Shivakumar Thiagarajan1, Aamir Yousuf2, Ratan Shetty3, Harsh Dhar4, Yash Mathur5, Deepa Nair5, Sandeep Basu6, Asawari Patil7, Shubadha Kane8, Sarbani Ghosh-Laskar9, Devendra Chaukar5. 1. Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, 400012, India. drshiva78in@gmail.com. 2. Department of ENT, Government Medical College, Srinagar, India. 3. Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Varanasi, India. 4. Narayana Superspeciality Hospital, Howrah, Kolkata, West Bengal, India. 5. Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, 400012, India. 6. Department of Nuclear Medicine, Radiation Medicine Centre, Mumbai, Maharashtra, India. 7. Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India. 8. Consultant Oncopathologist, Nanavati Superspeciaility Hospital, Mumbai, Maharashtra, India. 9. Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
Abstract
BACKGROUND: Poorly differentiated thyroid cancer (PDTC) is biologically more aggressive. Surgery remains the mainstay of treatment. The utility of radioactive iodine (RAI) after surgery is unclear. METHODS: In this retrospective study, patients treated between Jan 2012 and Dec 2017 were included. The demographic, clinical and treatment-related details, including RAI ablation, were recorded and their survival analyzed. RESULTS: Thirty-five patients fulfilled the eligibility criteria. Majority was treatment naïve at presentation. All patients underwent surgery followed by RAI ablation, with a cumulative median dose of 220 mCi (range 40-1140). Sixteen patients received more than one radioiodine treatment for distant metastases. Incomplete resection, age > 45 years and the presence of distant metastasis influenced survival the most. The 3-year PFS of patients with PDTC was 69%. CONCLUSION: All patients in our series showed uptake and responded to treatment. Further use of molecular markers and functional molecular imaging would better our understanding of this entity.
BACKGROUND: Poorly differentiated thyroid cancer (PDTC) is biologically more aggressive. Surgery remains the mainstay of treatment. The utility of radioactive iodine (RAI) after surgery is unclear. METHODS: In this retrospective study, patients treated between Jan 2012 and Dec 2017 were included. The demographic, clinical and treatment-related details, including RAI ablation, were recorded and their survival analyzed. RESULTS: Thirty-five patients fulfilled the eligibility criteria. Majority was treatment naïve at presentation. All patients underwent surgery followed by RAI ablation, with a cumulative median dose of 220 mCi (range 40-1140). Sixteen patients received more than one radioiodine treatment for distant metastases. Incomplete resection, age > 45 years and the presence of distant metastasis influenced survival the most. The 3-year PFS of patients with PDTC was 69%. CONCLUSION: All patients in our series showed uptake and responded to treatment. Further use of molecular markers and functional molecular imaging would better our understanding of this entity.
Authors: Pia Adam; Stefan Kircher; Iuliu Sbiera; Viktoria Florentine Koehler; Elke Berg; Thomas Knösel; Benjamin Sandner; Wiebke Kristin Fenske; Hendrik Bläker; Constantin Smaxwil; Andreas Zielke; Bence Sipos; Stephanie Allelein; Matthias Schott; Christine Dierks; Christine Spitzweg; Martin Fassnacht; Matthias Kroiss Journal: Front Endocrinol (Lausanne) Date: 2021-08-12 Impact factor: 5.555